CLCS (Cell Source) 50-Day SMA: $0.81 (As of Jun. 26, 2026)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.82
View Full Analysis

What is Cell Source 50-Day SMA?

Cell Source CLCS +9.33% 35 50-Day SMA is $0.81 as of Jun. 26, 2026. GuruFocus rates CLCS with a GF Score™ of 35/100.

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2026-06-26), Cell Source's 50-Day SMA is $0.81. It's 20-Day SMA is $0.79 and 200-Day SMA is $0.65.

Cell Source  (OTCPK:CLCS) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.

Cell Source 50-Day SMA Related Terms

CLCS vs EDSA, CTXR, ASBP: 50-Day SMA Comparison

For the Biotechnology subindustry, Cell Source's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source 50-Day SMA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Cell Source's 50-Day SMA falls into.


CLCS
35GF Score
Cell Source Inc CLCS
50-Day SMA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source  (OTCPK:CLCS) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 50-Day SMA →
What does a 50-Day SMA of $0.81 mean?
Cell Source (CLCS) has a 50-Day SMA of $0.81 as of Jun. 26, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Cell Source and its competitors.
Is Cell Source's 50-Day SMA too high?
Cell Source's current 50-Day SMA is $0.81. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's 50-Day SMA compare to EDSA and CTXR?
Cell Source's 50-Day SMA of $0.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Cell Source and its competitors. Cell Source's current 50-Day SMA is $0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current 50-Day SMA of $0.81. The current 50-Day SMA is $0.81. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Cell Source (CLCS), the current 50-Day SMA is $0.81 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.82
Price